T2 Biosystems Inc. (NASDAQ:TTOO) does about 14.24M shares in volume on a normal day but saw 15872259 shares change hands in Monday trading. The company now has a market cap of 229.27M USD and an enterprise value of about $238.98M. Its current market price is $1.56, marking an increase of 0.65% compared to the previous close of $1.55. The 52 week high reached by this stock is $3.21 whilst the lowest price level in 52 weeks is $0.23. The script in recent trading has seen the stock touch a high of $1.59 and a low of $1.50.

T2 Biosystems Inc. (TTOO) has a 20-day trading average at $1.6050 and the current price is -51.40% off the 52-week high compared with 563.83% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.5357 and its 200-day simple moving average is $1.0711. If we look at the stock’s price movements over the week, volatility stands at 5.41%, which increases to 8.90% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 50.11 to suggest the stock is neutral.

FactSet Research has provided data showing that 3 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 26, 2019 when Janney downgraded the stock to “Neutral” and issued a price target of . Alliance Global Partners also downgraded the stock to “Neutral” from Buy on August 01, 2019 at a price target of .

The current price level is -2.99%, 2.01%, and 45.55% away from its SMA20, SMA50, and SMA200 respectively, with the TTOO price moving below the 50-day SMA on August 31. T2 Biosystems Inc. (TTOO) stock is up 0.65% over the week and -6.02% over the past month. Its price is 33.33% year-to-date and 17.29% over the past year.

The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.09 above consensus estimates by $0.06. The company’s next earnings report is expected on 10/29/2020, with forecasts estimating quarterly EPS at -$0.08 and -$0.43 for whole year. TTOO’s earnings per share are forecast to grow by 66.90% this year and 37.20% over next year. Expected sales for next quarter are $8.65 million, which analysts say will come at $18.9 million for the current fiscal year and next year at $34.75 million. In addition, estimates put the company’s current quarterly revenue at an average of $5.15 million.

Its 12-month price target is $3.50. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $3.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $4.00.

Outstanding shares total 120.29M with insiders holding 5.94% of the shares and institutional holders owning 9.38% of the company’s common stock. The company has a return on investment of -584.90% and return on equity of 299.10%. The beta has a value of 1.09. Price to sales ratio is 23.40.

According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in T2 Biosystems Inc. (TTOO) to 3,158,573 shares, mirroring a recent drop by 0.00%. Vanguard Total Stock Market Index dumped 0.0 shares of T2 Biosystems Inc. common stock bringing its total worth to about $5.24 million at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which added 69381.0 shares to end up with 1,330,296 shares worth $2.21 million. Fidelity Extended Market Index Fu cut their holdings by -13.43% in the company over the course of the most recent quarter. It now holds a 0.35% position in T2 Biosystems Inc. thanks to 0.42 million shares amounting to $0.7 million.